Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-9966

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer ; volume:39 ; number:1 ; day:7 ; month:9 ; year:2020 ; pages:1-16 ; date:12.2020
Journal of experimental & clinical cancer research ; 39, Heft 1 (7.9.2020), 1-16, 12.2020

Creator: Camorani, Simona
Passariello, Margherita
Agnello, Lisa
Esposito, Silvia
Collina, Francesca
Cantile, Monica
Bonito, Maurizio Di
Ulasov, Ilya V.
Fedele, Monica
Zannetti, Antonella
Lorenzo, Claudia De
Cerchia, Laura

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13046-020-01694-9

URN: urn:nbn:de:101:1-2020102717520400512375

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:20 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Camorani, Simona
Passariello, Margherita
Agnello, Lisa
Esposito, Silvia
Collina, Francesca
Cantile, Monica
Bonito, Maurizio Di
Ulasov, Ilya V.
Fedele, Monica
Zannetti, Antonella
Lorenzo, Claudia De
Cerchia, Laura
SpringerLink (Online service)

Other Objects (12)

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Characterizing triple-negative breast cancer tumors

Triple-Negative Breast Cancer: Multimodality Appearance

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Characterizing triple-negative breast cancer tumors

Triple-Negative Breast Cancer: Multimodality Appearance

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Characterizing triple-negative breast cancer tumors

Triple-Negative Breast Cancer: Multimodality Appearance

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Characterizing triple-negative breast cancer tumors

Triple-Negative Breast Cancer: Multimodality Appearance

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Characterizing triple-negative breast cancer tumors

Triple-Negative Breast Cancer: Multimodality Appearance

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer

Metastatic Triple-Negative Breast Cancer

Characterizing triple-negative breast cancer tumors

Triple-Negative Breast Cancer: Multimodality Appearance

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer

Related objects

Reset password